References
- Corsini, E., Sangiovanni, E., Avogadro, A., et al. 2012. In vitro characterization of the immunotoxic potential of several perfluorinated compounds (PFCs). Toxicol. Appl. Pharmacol. 258:248–255
- DeWitt, J. C., Peden-Adams, M. M., Keller, J. M., and Germolec, D. R. 2012. Immunotoxicity of perfluorinated compounds: Recent developments. Toxicol. Pathol. 40:300–311
- Dietert, R. R. 2009. Developmental immunotoxicology: Focus on health risk. Chem. Res. Toxicol. 22:17–23
- Grandjean, P., Clapp, R. 2014. Changing interpretation of human health risks from perfluorinated compounds. Public Health Rep. 129:482–485
- Grandjean, P., Andersen, E. W., Budtz-Jorgensen, E., et al. 2012. Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. JAMA, 307:391–397
- Granum, B., Haug, L. S., Namork, E., et al. 2013. Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood. J. Immunotoxicol. 10:373–379
- Haug, L. S., Thomsen, C., Becher, G. 2009. A sensitive method for determination of a broad range of perfluorinated compounds in serum suitable for large-scale human biomonitoring. J. Chromatogr. 1216:385–393
- Kato, K., Wong, L. Y., Jia, L. T., et al. 2011. Trends in exposure to polyfluoroalkyl chemicals in the U.S. Population: 1999-2008. Environ. Sci. Technol. 45:8037–8045
- Keil, D. E., Mehlmann, T., Butterworth, L., and Peden-Adams, M. M. 2008. Gestational exposure to perfluorooctane sulfonate suppresses immune function in B6C3F1 mice. Toxicol. Sci. 103:77–85
- Looker, C., Luster, M. I., Calafat, A. M., et al. 2014. Influenza vaccine response in adults exposed to perfluorooctanoate and perfluorooctanesulfonate. Toxicol. Sci. 138:76–88